These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20024740)

  • 21. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
    Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
    HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once-daily dosing of nevirapine in HAART.
    Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
    Grossberg R; Zhang Y; Gross R
    J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.
    Moreno A; Perez-Elías MJ; Casado JL; Muñoz V; Antela A; Dronda F; Navas E; Fortún J; Quereda C; Moreno S
    Antivir Ther; 2000 Dec; 5(4):243-8. PubMed ID: 11142618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.
    Yasuda JM; Miller C; Currier JS; Forthal DN; Kemper CA; Beall GN; Tilles JG; Capparelli EV; McCutchan JA; Haubrich RH;
    Antivir Ther; 2004 Oct; 9(5):753-61. PubMed ID: 15535413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
    Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
    HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
    Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
    Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
    Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.
    Weber R; Christen L; Christen S; Tschopp S; Znoj H; Schneider C; Schmitt J; Opravil M; Günthard HF; Ledergerber B;
    Antivir Ther; 2004 Feb; 9(1):85-95. PubMed ID: 15040540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to antiretroviral therapy in pediatric patients with human immunodeficiency virus (HIV-1).
    Burack G; Gaur S; Marone R; Petrova A
    J Pediatr Nurs; 2010 Dec; 25(6):500-4. PubMed ID: 21035017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Literacy, education and adherence to antiretroviral therapy in The Gambia.
    Hegazi A; Bailey RL; Ahadzie B; Alabi A; Peterson K
    AIDS Care; 2010 Nov; 22(11):1340-5. PubMed ID: 20711888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy.
    Ing EC; Bae JW; Maru DS; Altice FL
    AIDS Behav; 2013 Jan; 17(1):113-21. PubMed ID: 22105340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
    Pérez-Molina JA; Suárez-Lozano I; Del Arco A; Teira R; Bachiller P; Pedrol E; Martínez-Alfaro E; Domingo P; Mariño A; Ribera E; Antela A; de Otero J; Navarro V; González-García J;
    HIV Clin Trials; 2011; 12(1):1-8. PubMed ID: 21388936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study.
    Pérez Molina JA; Rillo MM; Suárez-Lozano I; Casado Osorio JL; Cobo RT; González PR; Clotet EP; Jerez AH; Pedrol PD; Royuela A; Díaz EB; Esteban H; González-García J
    Curr HIV Res; 2010 Oct; 8(7):521-30. PubMed ID: 21073441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.